ScholarLens Back to search
2013•NeurologyRequires access

Gastrointestinal Tolerability Events in Relapsing–Remitting Multiple Sclerosis (RRMS) Patients Treated with Oral BG-12 (Dimethyl Fumarate) in DEFINE and CONFIRM (P01.164)

Leslie A. Meltzer, Krzysztof W. Selmaj, Ralf Gold, Robert J. Fox, Eva Havrdová, Gavin Giovannoni, Amy Pace, Mark Novas, Christophe Hotermans, Katherine T. Dawson, J. Theodore Phillips

Open publisher page 3 citations

Abstract

OBJECTIVE: To characterize gastrointestinal (GI) adverse events (AEs) in RRMS patients treated with BG-12 (dimethyl fumarate) twice daily (BID) in the DEFINE and CONFIRM studies.

About this research paper

What this paper is about

OBJECTIVE: To characterize gastrointestinal (GI) adverse events (AEs) in RRMS patients treated with BG-12 (dimethyl fumarate) twice daily (BID) in the DEFINE and CONFIRM studies.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To characterize gastrointestinal (GI) adverse events (AEs) in RRMS patients treated with BG-12 (dimethyl fumarate) twice daily (BID) in the DEFINE and CONFIRM studies.

Key concepts: Dimethyl fumarate, Medicine, Nausea, Vomiting, Tolerability, Abdominal pain, Placebo, Gastroenterology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Gastrointestinal Tolerability Events in Relapsing–Remitting Multiple Sclerosis (RRMS) Patients Treated with Oral BG-12 (Dimethyl Fumarate) in DEFINE and CONFIRM (P01.164) — Research Paper | ScholarLens